Holen Sie sich die Stockscreener-App
1.01
0.73%
-0.01
Handel nachbörslich:
1.01
Schlusskurs vom Vortag:
$1.00
Offen:
$1
24-Stunden-Volumen:
714.93K
Relative Volume:
1.84
Marktkapitalisierung:
$29.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.73M
KGV:
-0.3607
EPS:
-2.8
Netto-Cashflow:
$-53.29M
1W Leistung:
-8.93%
1M Leistung:
-5.46%
6M Leistung:
-56.27%
1J Leistung:
-93.86%
1-Tages-Spanne:
$0.975
$1.03
1-Wochen-Bereich:
$0.975
$1.105
52-Wochen-Spanne:
$0.87
$22.22
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Firmenname
An 2 Therapeutics Inc
Sektor
Branche
Telefon
(650) 331-9090
Adresse
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Vergleichen Sie ANTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ANTX | 1.01 | 29.84M | 0 | -64.73M | -53.29M | -2.80 |
| VRTX | 467.12 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study - The Manila Times
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 - GlobeNewswire
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail
Cognition Therapeutics Presents Poster of Participant - GlobeNewswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - BioSpace
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease - StockTitan
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain - GlobeNewswire
Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire
Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ... - Yahoo Finance
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of - GlobeNewswire
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - GlobeNewswire
Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - Yahoo Finance
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - StockTitan
Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease - Business Wire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - StockTitan
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024 - Business Wire
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update - GlobeNewswire
Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 - StockTitan
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 - Yahoo Finance
Araris Doubles Down With Dual-payload ADC - BioProcess Online
Black Diamond Therapeutics Announces Initial Phase 2 Data - GlobeNewswire
Ildikó Enyedi working on her new feature, Silent Friend - Cineuropa
Boss Brown calls on Ayr players to step up after losing top scorer for season - Ayr Advertiser
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations - StockTitan
Black Diamond Therapeutics to Host Webcast Presentation of - GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC - Yahoo Finance
Scott Brown admits Anton Dowds injury is huge blow for Ayr United as he challenges others to step up - Daily Record
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio reports promising ADI-001 therapy data - Investing.com
Australia's Amplia Therapeutics rises as US FDA fast-tracks cancer drug - XM
Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting - BioSpace
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) - Business Wire
Agatha All Along Episode 2 Cast & Characters Guide (Photos) - The Direct
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 - GlobeNewswire
iView Therapeutics completes enrollment in phase 1/2 trial for ophthalmic eyelid wipe for the treatment of dry eye disease - Ophthalmology Times
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders - GlobeNewswire
IVIEW Therapeutics Inc. Completes Patient Recruitment for Phase 1/2 Trial of IVW-1001 Ophthalmic Eyelid Wipe in Dry Eye Disease Patients - PR Newswire
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 - Yahoo Finance
Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysi - Yahoo Finance
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration - PR Newswire
Intellia Therapeutics to Present Data from the Phase 2 - GlobeNewswire
Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting - Yahoo Finance
Finanzdaten der An 2 Therapeutics Inc-Aktie (ANTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.27%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):